Literature DB >> 29114397

False-positive galactomannan assay in broncho-alveolar lavage after enteral nutrition solution inhalation: a case report.

Olivier Lheureux1, Isabel Montesinos2, Olivier Taton3, Martine Antoine4, Jean-Charles Preiser1, Joelle Nortier5, Jacques Creteur1, Frederique Jacobs6, David Grimaldi1.   

Abstract

Introduction. Diagnosis of invasive aspergillosis is challenging and the gold standard for definite diagnosis remains histopathological tissue examination. However, invasive procedures such as lung biopsy are often not feasible in critically ill patients. The detection of fungal cell wall components like Aspergillus galactomannan in broncho-alveolar lavage remains a key component of the diagnostic procedure. False-positive of the Aspergillus galactomannan assay is not frequent. Case presentation. We report a case of positive galactomannan in broncho-alveolar lavage fluid after enteral nutrition aspiration without signs of invasive aspergillosis. Galactomannan was positive in the enteral nutrition solution. Conclusion. Physicians should be aware of this previously unrecognized cause of false-positive galactomannan in broncho-alveolar fluid which can result in unnecessary treatments.

Entities:  

Keywords:  Aspergillosis; Pneumonia; feeding solution; fungal infection; immunosuppression; nutritional support; respiratory failure; voriconazole

Year:  2017        PMID: 29114397      PMCID: PMC5643004          DOI: 10.1099/jmmcr.0.005116

Source DB:  PubMed          Journal:  JMM Case Rep        ISSN: 2053-3721


Abbreviations

BAL, broncho-alveolar lavage; GM, galactomannan; IA, invasive aspergillosis; ICU, intensive care unit; VAP, ventilator-associated pneumonia.

Introduction

We describe the first report of a false-positive broncho-alveolar galactomannan due to aspiration of enteral nutrition. As enteral nutrition solutions are prescribed daily in critically ill patients and aspiration pneumonia is a common complication in intensive care, physicians should consider this possibility in case of broncho-alveolar lavage positive galactomannan assay under artificial enteral feeding. We believe this finding will be of great interest to microbiologists and physicians, especially to those in contact with patients in intensive care.

Case report

A 65-year-old man was admitted in our intensive care unit (ICU) for pneumonia with septic shock. He was a heart transplant recipient since 1998 and had a renal graft in 2015 because of immunosuppressive treatment toxicity. Current immunosuppressive therapy consisted of methylprednisolone, mycophenolate mofetil and cyclosporine. Septic shock was associated with acute renal failure and severe acute respiratory distress syndrome requiring mechanical ventilation. No infectious pathogen was identified. The shock resolved in 4 days but respiratory conditions, only slowly improved, and the presence of a severe ICU-acquired weakness required a tracheotomy after 10 days of mechanical ventilation. The ICU stay was further complicated by a ventilator-associated pneumonia (VAP) due to Pseudomonas aeruginosa, a primary Enterococcus faecalis bacteremia and a severe herpetic stomatitis. A new respiratory deterioration at day 23 led to suspicion of a new episode of VAP treated by meropenem. Bronchoscopy revealed an important aspiration of enteral nutrition solution (Nutrison Protein Plus multifibre; Nutricia) due to incorrect position of the nasogastric tube. The procedure was followed by a pneumothorax, with pleural effusion, which required chest tube drainage. The pleural liquid had the same macroscopic aspect as the enteral nutrition solution. Aspergillus galactomannan (GM) assays performed in broncho-alveolar lavage (BAL) and pleural fluid, using the one-stage commercialized immunoenzymatic sandwich microplate assay (Platelia Aspergillus Ag; Bio-Rad), were highly positive in both fluids [optical density (OD) index 4.6 and >6, respectively; cut-off value >1]. Serum GM OD index was 0.08 (cut-off value >0.50) and fungal cultures of both BAL and pleural fluid remained sterile. We initiated voriconazole treatment and completed the work up with chest and sinus CT scans; both showed no signs suggestive of invasive fungal infection (see supplementary material). Considering these inconsistent findings for an invasive aspergillosis (IA), we performed Aspergillus GM detection in the enteral nutrition solution, which proved highly positive (index >6) whereas fungal culture remained negative. We therefore tested two other commercialized enteral nutrition solutions [Isosource standard fibre(Nestlé) and Fresubin original fibre (Fresenius Kabi)] also used in our institution and confirmed that all were also higher than the upper detection threshold (index >6). We therefore stopped voriconazole after 8 days of treatment. Evolution was favourable without any further fungal infection.

Discussion

Species of the genus Aspergillus are ubiquitous in nature, and inhalation of infectious conidia is a common event that can give rise to various clinical conditions depending essentially on the host’s immunological status. IA occurs most frequently in the setting of severe immunosuppression (prolonged neutropenia, haematopoietic stem-cell transplantation, solid organ transplantation or acquired immune deficiency syndrome) [1]. Diagnosis of IA is challenging and the gold standard for definite diagnosis remains histopathological tissue examination. However, invasive procedures such as lung biopsy are often not feasible in patients with severe respiratory insufficiency and critical illness [2]. Despite the lack of sufficiently sensitive or specific non-invasive test to establish definite diagnosis, the detection of a fungal cell wall component like Aspergillus GM remains a key component of the diagnostic procedure. Aspergillus GM are polysaccharides released during growth of the fungus and are detected by ELISA in biological fluid. In the serum, a positive GM is a strong argument in favour of invasive aspergillosis but the test lacks sensitivity [3]. Therefore, detection of Aspergillus GM has been proposed in the BAL and seems to have a greater sensitivity. According to a meta-analysis, BAL GM sensitivity and specificity reach 92 and 96 %, respectively with a threshold of 1.5 µg l−1 in adult haematology patients [4]. Results are however lower in other immunosuppressed patient populations such as solid organ transplant recipients. A false-positive result of the Aspergillus GM assay is not frequent. In BAL, false-positive GM assays have been observed in case of histoplasmosis [5] and in other mycoses [6, 7]. Indeed, some fungal species such as Penicillium and Paecilomyces have shown cross-reactivity with the rat EBA-2 monoclonal antibody used in our report, which has been characterized in previous studies [8]. False-positive BAL GM have been demonstrated after lavage with Plasmalyte (Baxter, Lessines, Belgium) and under treatment with piperacillin-tazobactam [9, 10]. Several reports incriminate GM-containing foods (pasta, rice, energy drinks, etc) as the source of positive serum GM through a chemotherapy-induced permeability of the intestinal mucosal barrier [11-13] but this was not reported in BAL fluids. A positive serum GM test linked to enteral feeding products has been mentioned exceptionally [14]. To the best of our knowledge, this is the first report of positive BAL GM assay induced by aspiration of enteral nutrition solution. Whether subclinical micro-aspiration of enteral nutrition solutions could also induce false-positive BAL GM should be further studied.

Conclusion

This is the first report of a false-positive BAL GM due to aspiration of enteral nutrition. Physicians should consider this possibility in case of BAL positive GM assay under artificial enteral feeding.
  14 in total

1.  Transient aspergillus antigenaemia: think of milk.

Authors:  Jean-Pierre Gangneux; Dominique Lavarde; Stéphane Bretagne; Claude Guiguen; Virginie Gandemer
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

2.  False-positive Aspergillus galactomannan assay in solid organ transplant recipients with histoplasmosis.

Authors:  P Vergidis; R C Walker; D R Kaul; C A Kauffman; A G Freifeld; D C Slagle; A B Kressel; L J Wheat
Journal:  Transpl Infect Dis       Date:  2011-09-26       Impact factor: 2.228

3.  Positive result of the Aspergillus galactomannan antigen assay using bronchoalveolar lavage fluid from a patient with an invasive infection due to Lichtheimia ramosa.

Authors:  Rafael Borrás; Patricia Roselló; Marifina Chilet; Dayana Bravo; Juan García de Lomas; David Navarro
Journal:  J Clin Microbiol       Date:  2010-06-16       Impact factor: 5.948

4.  Plasmalyte as a cause of false-positive results for Aspergillus galactomannan in bronchoalveolar lavage fluid.

Authors:  Chadi A Hage; John M Reynolds; Michelle Durkin; L Joseph Wheat; Kenneth S Knox
Journal:  J Clin Microbiol       Date:  2006-12-13       Impact factor: 5.948

Review 5.  Invasive pulmonary mycosis due to Chaetomium globosum with false-positive galactomannan test: a case report and literature review.

Authors:  Malini R Capoor; Poojan Agarwal; Manoj Goel; Sarika Jain; Mandya Rudramurthy Shivaprakash; Prasanna Honnavar; Sunita Gupta; Arunaloke Chakrabarti
Journal:  Mycoses       Date:  2015-12-22       Impact factor: 4.377

6.  Aspergillus galactomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis.

Authors:  Seong Yeon Park; Sang-Oh Lee; Sang-Ho Choi; Heungsup Sung; Mi-Na Kim; Chang-Min Choi; Sang-Bum Hong; Yeon-Mok Oh; Tae Sun Shim; Younsuck Koh; Yang Soo Kim; Jun Hee Woo; Sung-Han Kim
Journal:  J Infect       Date:  2010-09-15       Impact factor: 6.072

7.  Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus.

Authors:  J P Latgé; H Kobayashi; J P Debeaupuis; M Diaquin; J Sarfati; J M Wieruszeski; E Parra; J P Bouchara; B Fournet
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

Review 8.  Approach to invasive pulmonary aspergillosis in critically ill patients.

Authors:  Despoina Koulenti; Jose Garnacho-Montero; Stijn Blot
Journal:  Curr Opin Infect Dis       Date:  2014-04       Impact factor: 4.915

Review 9.  Galactomannan detection for invasive aspergillosis in immunocompromised patients.

Authors:  Mariska M G Leeflang; Yvette J Debets-Ossenkopp; Junfeng Wang; Caroline E Visser; Rob J P M Scholten; Lotty Hooft; Henk A Bijlmer; Johannes B Reitsma; Mingming Zhang; Patrick M M Bossuyt; Christina M Vandenbroucke-Grauls
Journal:  Cochrane Database Syst Rev       Date:  2015-12-30

10.  Case report: false positive elevated serum-galactomannan levels after autologous hematopoietic stem cell transplantation caused by oral nutritional supplements.

Authors:  Tobias Rachow; Sebastian Dornaus; Herbert G Sayer; Beate Hermann; Andreas Hochhaus; Marie von Lilienfeld-Toal
Journal:  Clin Case Rep       Date:  2016-04-12
View more
  2 in total

1.  Challenges with Utilizing the 1,3-Beta-d-Glucan and Galactomannan Assays To Diagnose Invasive Mold Infections in Immunocompromised Children.

Authors:  Alice J Hsu; Pranita D Tamma; Sean X Zhang
Journal:  J Clin Microbiol       Date:  2021-08-18       Impact factor: 5.948

2.  Nebulized Amphotericin B in Mechanically Ventilated COVID-19 Patients to Prevent Invasive Pulmonary Aspergillosis: A Retrospective Cohort Study.

Authors:  Max Melchers; Arthur R H van Zanten; Moniek Heusinkveld; Jan Willem Leeuwis; Roel Schellaars; Hendrick J W Lammers; Freek J Kreemer; Pieter-Jan Haas; Paul E Verweij; Sjoerd H W van Bree
Journal:  Crit Care Explor       Date:  2022-05-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.